Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)
Con Edison(ED) Prnewswire·2024-06-20 19:30In ED patients that do not respond to PDE5i monotherapy~30-40% of ED patients do not respond to PDE5i treatmentData from this Phase 2 clinical study is expected by end of calendar year 2024Published clinical data and mechanisms of action support clinical study of bremelanotide in combination with a PDE5iPhase 3 clinical study with new co-formulated bremelanotide plus a PDE5i in ED patients that do not respond to PDE5i monotherapy expected to start in the 1st half of calendar year 2025CRANBURY, N.J., June 20 ...